ムラガキ　ヨシヒロ   MURAGAKI Yoshihiro   村垣　善浩    所属   医学部 医学科（東京女子医科大学病院）    職種   客員教授
論文種別	症例報告
言語種別	英語
査読の有無	査読あり
表題	Information-guided surgical management of gliomas using low-field-strength intraoperative MRI.
掲載誌名	正式名：Acta neurochirurgica. Supplementum 略　 称：Acta Neurochir Suppl (Wien) ISSNコード：00651419
巻・号・頁	109(2),pp.67-72
著者・共著者	MURAGAKI Yoshihiro†*, ISEKI Hiroshi, MARUYAMA Takashi, TANAKA Masahiko, SHINOHARA Chie, SUZUKI Takashi, YOSHIMITSU Kitaro, IKUTA Soko, HAYASHI Motohiro, CHERNOV Mikhail, HORI Tomokatsu, OKADA Yoshikazu, TAKAKURA Kintomo
担当区分	筆頭著者,責任著者
発行年月	2011/04
概要	BACKGROUND:Contemporary technological developments revolutionized management of brain tumors. The experience with information-guided surgery of gliomas, based on the integration of the various intraoperative anatomical, functional, and histological data, is reported.METHODS:From 2000 to 2009, 574 surgeries for intracranial gliomas were performed in our clinic with the use of intraoperative MRI (ioMRI) with magnetic field strength of 0.3T, updated neuronavigation, neurochemical navigation with 5-aminolevulinic acid, serial intraoperative histopathological investigations of the resected tissue, and comprehensive neurophysiological monitoring. Nearly half of patients (263 cases; 45.8%) were followed more than 2 years after surgery.FINDINGS:Maximal possible tumor resection, defined as radiologically complete tumor removal or subtotal removal leaving the residual neoplasm within the vital functionally-important brain areas, was attained in 569 cases (99.1%). The median resection rate constituted 95%, 95%, and 98%, for WHOFINDINGS:grade II, III, and IV gliomas, respectively. Actuarial 5-year survival was significantly worse in WHO grade IV gliomas (19%), but did not differ significantly between WHO grade III and II tumors (69% vs. 87%).CONCLUSIONS:Information-guided management of gliomas using low-field-strength ioMRI provides a good opportunity for maximal possible tumor resection, and may result in survival advantage, particularly in patients with WHO grade III neoplasms.
DOI	10.1007/978-3-211-99651-5_11
PMID	20960323